TLPH

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Wall Street analysts forecast TLPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLPH is 3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Talphera Inc revenue for the last quarter amounts to 1,000 USD, decreased % YoY.

Talphera Inc. EPS for the last quarter amounts to -0.11 USD, decreased -15.38 % YoY.

Talphera Inc (TLPH) has 13 emplpoyees as of December 16 2025.

Today TLPH has the market capitalization of 55.00M USD.